Morpholine → HCID 11055696, compound
Reaction equation
[NH:1]1[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.O.[C:8]([NH:15][C@H:16]([C:21](O)=[O:22])[CH2:17][CH:18]([CH3:20])[CH3:19])([O:10][C:11]([CH3:14])([CH3:13])[CH3:12])=[O:9]>>[C:8]([NH:15][C@H:16]([C:21]([N:1]1[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1)=[O:22])[CH2:17][CH:18]([CH3:19])[CH3:20])([O:10][C:11]([CH3:12])([CH3:14])[CH3:13])=[O:9]Participants
Procedure
In substantially the same manner as Working Example 2, morpholine (1.76 ml) was condensed with Boc-L-leucine monohydrate (5.00 g) to give Boc-L-leucylmorpholine (5.76 g) as a colorless oily product (yield 95%). A portion (2.00 g) of this product was taken, and the Boc group was deprotected by using TFA. The resultant compound was treated in substantially the same manner as Working Example 8 to afford L-leucylmorpholine hydrochloride (1.52 g) as a white powdery product (yield 96%). A portion (807 mg) of this product was condensed, in substantially the same manner as Working Example 8, with (2S,3S)-ethyl hydrogen N-Z-aziridine-2,3-dicarboxylate (Compound 1, 100 g) to afford the above-titled compound (Compound 17; 1.06 g) as a white powdery product (yield 65%).
Sources & evidence
- ORD record
- ord-2298247bde354398b336c6705717afff
- Source dataset
- uspto-grants-1997_09
- Patent number
- US05668128
Reaction notes
Loading…